Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca Foundation filed notice under Rule 144 to sell 8,333 shares of Erasca, Inc. common stock through Merrill Lynch on or about 02/17/2026 on NASDAQ, with an aggregate market value of $99,245.03.
The foundation acquired 10,193,557 common shares as a donation from Erasca, Inc. on 07/20/2021. Over the past three months it has already sold 8,333 shares on each of 11/17/2025, 12/15/2025, and 01/15/2026, receiving gross proceeds of $21,626.50, $30,438.69, and $68,573.87 respectively.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 16,111,414 shares of Erasca Inc. common stock, representing 5.7% of the class as of 12/31/2025.
The firm reports sole power to vote and dispose of all 16,111,414 shares, with no shared voting or dispositive power. It states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Erasca.
Erasca, Inc. Chairman, CEO and 10% owner Jonathan E. Lim reported receiving a stock option grant covering 2,000,000 shares of common stock. The option has an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48 of the option shares vest each month on the 29th (or the last day of February), beginning in February 2026, so long as Lim continues to provide service to Erasca on each vesting date. After this grant, he beneficially owns options for 2,000,000 shares.
Erasca, Inc. reported insider equity activity by its CFO and CBO, David M. Chacko. On 12/15/2025, he acquired 17,793 shares of common stock at $1.1943 per share through the company’s 2021 Employee Stock Purchase Plan, bringing his directly held common shares to 279,980.
On 01/29/2026, he was granted a stock option for 640,000 shares of common stock with an exercise price of $10.31 per share. One forty-eighth of these option shares vest monthly starting in February 2026, conditioned on his continued service to Erasca.
Erasca, Inc. reported a new equity award for its Chief Medical Officer, Morris Shannon. A Form 4 shows a grant of stock options covering 625,000 shares of common stock, with an exercise price of $10.31 per share, dated January 29, 2026.
These options vest over four years: 1/48th of the shares vest each month on the 29th (or the last day of February), beginning in February 2026, as long as Shannon continues serving the company on each vesting date. All 625,000 options are reported as directly owned following this grant.
Erasca, Inc. director Michael David Varney received a stock option award reported as of January 29, 2026. The option covers 96,000 shares of common stock at an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48th of the option vests each month on the 29th day (or the last day of February), beginning in February 2026, so long as Varney continues providing service to Erasca on each vesting date.
Erasca, Inc. reported a stock option grant to its General Counsel and Corporate Secretary, Ebun Garner. The option covers 560,000 shares of Erasca common stock at an exercise price of $10.31 per share and was granted on January 29, 2026.
According to the vesting terms, 1/48th of the shares subject to the option vest monthly on the 29th of each month (or the last day of February), beginning in February 2026, as long as Garner remains in continuous service with the company. After this grant, Garner beneficially owns 560,000 stock options directly.
Erasca, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. The company also closed an upsized public offering of 25,875,000 common shares, including underwriters’ full overallotment exercise.
Erasca estimates net proceeds of $242.7 million from this January 2026 offering after underwriting discounts and expenses. Based on this cash position and the offering proceeds, the company estimates it has sufficient cash resources to fund operations into the first half of 2029. These figures are preliminary, unaudited and subject to completion of year-end financial procedures.
Erasca, Inc. entered into an underwriting agreement to sell 22,500,000 shares of its common stock at a public offering price of $10.00 per share, with underwriters purchasing at $9.40 per share. The company also granted the underwriters a 30-day option to buy up to 3,375,000 additional shares at the same public price, less discounts and commissions. Net proceeds to Erasca are expected to be about $211.0 million, or approximately $242.7 million if the option is fully exercised, after fees and expenses. The offering is expected to close on January 23, 2026, subject to customary closing conditions, and is being conducted under an effective shelf registration statement and related prospectus supplement.
Erasca, Inc. is conducting a primary offering of 22,500,000 shares of its common stock at $10.00 per share, for gross proceeds of $225.0 million and estimated net proceeds of about $211.0 million after underwriting fees and expenses. The company has granted underwriters a 30‑day option to purchase up to 3,375,000 additional shares.
Erasca plans to use the net proceeds, together with its existing cash, cash equivalents and marketable securities, to fund research and development of its oncology product candidates and other programs, and for working capital and general corporate purposes, with potential in-licensing or acquisitions as opportunities arise. As of September 30, 2025, Erasca had 283,711,805 shares outstanding, and investors in this offering will experience immediate dilution, with an estimated $8.18 per-share dilution based on the net tangible book value at that date.